DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

AstraZeneca PLC ADR closed 14.68% short of its 52-week high of $87.68, which the company achieved on August 30th.

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

Commenting on this year’s 2025 Best Workplaces in UAE™ list Mohammed AlShair, Executive Chairman of Great Place to Work® ...

AstraZeneca PLC (LON:AZN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as ...

AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...